Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40M9J | ISIN: US83558L3033 | Ticker-Symbol: O8Z
Lang & Schwarz
21.12.24
09:00 Uhr
2,520 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SONOMA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SONOMA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4802,56021.12.

Aktuelle News zur SONOMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
MiSNOA-Aktie erreicht 52-Wochen-Tief bei 2,44 US-Dollar1
06.12.SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges7
06.12.SNOA-Aktie erreicht 52-Wochen-Tief bei 2,47 US-Dollar4
SONOMA PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.12.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices201BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
21.11.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States252BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
21.11.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report2
11.11.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn-based Wound Care Hydrogel338BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
11.11.Sonoma Pharmaceuticals erhält FDA-Zulassung für Hydrogel9
11.11.Sonoma Pharmaceuticals gains FDA clearance for hydrogel2
08.11.Sonoma Pharmaceuticals GAAP EPS of -$0.59, revenue of $3.6M8
07.11.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results209Revenue increased 31% for the quarter compared to same period prior yearPositive cash flows from operations of $0.35 million for the quarterNet loss improved 59% for the quarter compared to same period...
► Artikel lesen
07.11.Sonoma Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
31.10.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf289BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous...
► Artikel lesen
22.10.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada246BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
22.10.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report2
21.10.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences238BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
20.09.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report1
19.09.Sonoma Pharmaceuticals regains Nasdaq compliance3
19.09.Sonoma Pharmaceuticals erfüllt wieder Nasdaq-Anforderungen10
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1